ANIP News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AN

Mkt Cap

$1.66B

Volume

267.98K

Next Earnings

November 6th

Loading chart

AN

ANIPANI Pharmaceuticals, Inc.

ANIP

Pay with—

Available Balance0.00

AN

Mkt Cap

$1.66B

Volume

267.98K

Next Earnings

November 6th

Chart Financials Earnings News About Insider Filings

Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?ANI Pharmaceuticals (ANIP) is highlighted as a stock with strong potential to beat upcoming earnings estimates. The company has demonstrated a consistent track record of earnings surprises, with an average surprise of 35.05% over the past two quarters. With a positive Earnings ESP of +6.45% and a Zacks Rank #3 (Hold), the stock shows indicators suggesting another earnings beat is likely.Zacks Investment Research · Oct 13, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarThe article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could beat their upcoming quarterly earnings estimates. ANI Pharmaceuticals (ANIP) has a +6.45% ESP ahead of its November 6, 2026 earnings release, while Regeneron (REGN) has a +0.23% ESP before reporting on October 30, 2026. Both stocks carry a Zacks Rank #3 (Hold) rating, and the article suggests that stocks with positive ESP combined with a Zacks Rank #3 or better have historically beaten earnings 70% of the time.Zacks Investment Research · Oct 13, 2026

How to Find Strong Medical Stocks Slated for Positive Earnings SurprisesThe article explains how to identify medical stocks poised for earnings surprises using the Zacks Earnings ESP (Expected Surprise Prediction) tool. It highlights that combining a positive ESP with a Zacks Rank #3 or better has historically produced 70% positive surprises and 28.3% average annual returns. Two medical stocks are featured as examples: Solventum (SOLV) with a +2.81% ESP and ANI Pharmaceuticals (ANIP) with a +6.45% ESP, both expected to report earnings in early November 2026.Zacks Investment Research · Oct 6, 2026

ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ETANI Pharmaceuticals announced it will release its second quarter 2026 financial results on August 7, 2026, with executives hosting a webcast and conference call. The company also announced positive six-month topline data from its Phase 4 SYNCHRONICITY trial evaluating fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis, meeting both co-primary endpoints.GlobeNewswire Inc. · Jul 24, 2026

ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious UveitisANI Pharmaceuticals reported positive Phase 4 trial results for ILUVIEN (fluocinolone acetonide intravitreal implant) in treating chronic non-infectious uveitis affecting the posterior segment. The trial met both co-primary endpoints with statistically significant improvements in visual acuity (+3.6 letters) and central subfield thickness reduction (-157.5 microns) at 6 months. Safety profile was consistent with prior trials, with ocular hypertension (6%) and cataract (5%) as the most common adverse events.GlobeNewswire Inc. · Jul 13, 2026

ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% RunANI Pharmaceuticals CFO Stephen Carey sold 3,313 shares worth $285,000 on July 2, 2026, through a pre-established Rule 10b5-1 trading plan adopted in March. The sale represented only 2% of his direct holdings, leaving him with approximately $15.3 million in company stock. The transaction involved exercising options at $49.51 and selling at $86.00 per share. Despite the stock's 32% one-year return, the article characterizes this as routine portfolio management, noting the company's strong fundamentals including 20.5% Q1 revenue growth and raised full-year guidance.The Motley Fool · Jul 13, 2026

Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 MillionGlobal Alpha Capital Management sold 228,895 shares of Ani Pharmaceuticals (ANIP) in Q1 2026, worth approximately $17.87 million, reducing its position by about 39%. The sale reduced ANIP from Global Alpha's ninth-largest holding to outside the fund's top five positions. Despite strong Q1 earnings with 20.5% sales growth and raised 2026 guidance, the stock has underperformed the S&P 500 significantly.The Motley Fool · May 11, 2026

ANI Pharma Insider Sells 4,772 Shares as Revenue Hits $883 Million in 2025An ANI Pharmaceuticals executive sold 4,772 shares worth $357,471 on March 11, 2026, representing routine portfolio trimming rather than a bearish signal. The company reported record 2025 revenue of $883.4 million (up 43.8% YoY) driven by strong rare disease segment growth, with management guiding for over $1 billion in 2026 revenue.The Motley Fool · Mar 27, 2026

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ETANI Pharmaceuticals announced it will release its fourth quarter and full year 2025 financial results on February 27, 2026, prior to market open. The company expects full year 2025 total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be within or above guidance ranges. A conference call will be hosted by CEO Nikhil Lalwani and other executives to discuss the results.GlobeNewswire Inc. · Feb 13, 2026

ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked AwayStonepine Capital Management fully exited its position in ANI Pharmaceuticals, selling 38,597 shares worth $2.52 million in Q3. Despite ANI's strong fundamentals—with Q3 revenue surging 54% YoY to $227.8 million and stock up 49% over the past year—the fund's exit appears to be a portfolio rebalancing move toward earlier-stage biotech rather than a loss of confidence. ANI's future returns will depend on sustained rare disease growth and margin discipline rather than multiple expansion.The Motley Fool · Dec 28, 2025

to start trading

AN

ANIPANI Pharmaceuticals, Inc.

ANIP

Pay with—

Available Balance0.00

Your PositionYou don't own any ANIP yet.

Related Tickers

Earnings